Regulation of Oncogene 14-3-3zeta for Cancer Treatment ID: 2015-005
A groundbreaking approach to cancer treatment through the regulation of the oncogene 14-3-3zeta.
Photo by AMELIE-BENOIST / BSIP
Technology Overview
This invention involves a novel method for regulating the oncogene 14-3-3zeta (14-3-3z), crucial in tumor growth and chemoresistance in cancer. It is based on the acetylation and deacetylation mechanisms of 14-3-3z by histone deacetylase 6 (HDAC6) and GCNSLl, respectively. Inhibiting HDAC6 or activating GCNSLl leads to the deactivation of 14-3-3z, offering a new therapeutic target in cancer treatment.
Key Advantages
- Provides a new target for cancer therapy by regulating 14-3-3z
- Utilizes HDAC6 inhibitors, which are already available in clinical settings
- Offers a significant advancement in treating tumors and overcoming chemoresistance
Problems Addressed
- Lack of specific treatments targeting the oncogene 14-3-3z
- Challenges in treating tumors that are resistant to current chemotherapy methods
Market Applications
- Oncology: Targeted cancer therapy using small molecule inhibitors
- Pharmaceutical development of new cancer treatments focusing on gene regulation
Additional Information
Technology ID: 2015-005
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report